MIV Therapeutics (OTCBB:MIVT)(FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, is scheduled present the highly encouraging development progress of the Company's Hydroxyapatite (HAp) coatings for coronary stents and other devices at the 19th International Symposium on Ceramics in Medicine conference in Chengdu, China.
